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Abstract 1 
 2 
Phosphoinositides are small phospholipids that control diverse cellular downstream signaling 3 
events. Their spatial and temporal availability is tightly regulated by a set of specific lipid 4 
kinases and phosphatases. Congenital muscular dystrophies are hereditary disorders 5 
characterized by hypotonia and weakness from birth with variable eye and central nervous 6 
system involvement. In individuals exhibiting congenital muscular dystrophy, early-onset 7 
cataracts and mild intellectual disability but normal cranial magnetic resonance imaging, we 8 
identified bi-allelic mutations in INPP5K, encoding inositol polyphosphate-5-phosphatase K. 9 
Mutations impaired phosphatase activity towards the phosphoinositide phosphatidylinositol 10 
(4,5)-bisphosphate or altered the subcellular localization of INPP5K. Downregulation of 11 
INPP5K orthologs in zebrafish embryos disrupted muscle fiber morphology and resulted in 12 
abnormal eye development. These data link congenital muscular dystrophies to defective 13 
phosphoinositide 5-phosphatase activity that is becoming increasingly recognized for its role 14 
in mediating pivotal cellular mechanisms contributing to disease. 15 
 
4
Introduction 1 
 2 
Congenital muscular dystrophies (CMD) are clinically and genetically heterogeneous 3 
inherited disorders in which muscle weakness typically manifests at birth or in infancy 1. 4 
Delayed motor milestones, poor motor abilities and joint or spinal rigidity are often the 5 
presenting features. Muscle weakness may remain stable or deteriorate over time. 6 
Complications include contractures, spinal deformities and respiratory compromise. Cardiac 7 
involvement, cognitive impairment, white matter and structural abnormalities of the brain, 8 
seizures and eye abnormalities may occur depending on the genetic cause. For example, early 9 
cataracts, cerebellar atrophy and variable intellectual disability suggest Marinesco-Sjögren 10 
syndrome (MSS [MIM: 248800]), which also features characteristic ultrastructural muscle 11 
pathology (dense perinuclear membranous structures) 2-4. Most CMD are inherited in an 12 
autosomal recessive manner with the exception of de-novo dominant inheritance in CMD 13 
caused by LMNA mutations (MIM: 613205) and some cases of Ullrich CMD (MIM: 254090). 14 
Mutations occur in genes encoding structural proteins of the extracellular matrix, enzymes 15 
catalyzing protein glycosylation, and proteins of the endoplasmic reticulum (ER) and nuclear 16 
envelope 5. Mutations can be identified in 25%-50% of CMD cases 6, suggesting the existence 17 
of unidentified additional genes harboring mutations causing CMD and underscoring the need 18 
for ongoing investigation into the genetic causes of CMD. 19 
 20 
Phosphatidylinositol (PtdIns) is a membrane phospholipid, which can be reversibly 21 
phosphorylated at the 3, 4, and 5 positions of the inositol ring. Resulting phosphoinositides 22 
provide the basis for the synthesis of the second messengers diacylglycerol and inositol 23 
(1,4,5)-trisphosphate (Ins(1,4,5)P3, IP3), which mobilize intracellular calcium and activate 24 
protein kinase C 7. Moreover, through interactions between their phosphorylated head groups 25 
and protein modules, phosphoinositides recruit proteins to the cytosolic leaflet of membrane 26 
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bilayers where they regulate multiple processes including the assembly of signaling scaffolds, 1 
biogenesis of transport vesicles, endocytosis and secretion, actin nucleation, microtubule 2 
dynamics as well as transport of ions and metabolites 8-11. The spatial and temporal control of 3 
the presence of each phosphoinositide at plasma and organelle membranes 12 is ensured by the 4 
action of kinases and phosphatases that are differentially located on specific membranes 13. 5 
The relevance of proper phosphoinositide metabolism for cell and organ function is 6 
emphasized by the growing number of human diseases resulting from mutations in genes 7 
encoding enzymes that catalyze interconversion from one phosphoinositide to another 14. 8 
While such mutations have been identified in other inherited neurological and neuromuscular 9 
disorders, including Lowe oculocerebrorenal syndrome (MIM: 309000) 15, lethal congenital 10 
contractural syndrome type 3 (MIM: 611369) 16, X-linked myotubular myopathy (MIM: 11 
310400) 17 and hereditary polyneuropathies (MIM: 601382, MIM: 604563, MIM: 611228) 18-12 
21, no phosphoinositide metabolizing enzymes have been directly linked to CMD. Here we 13 
report that mutations in the gene encoding inositol polyphosphate-5-phosphatase K, INPP5K, 14 
cause a distinct form of CMD. 15 
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Material and Methods 1 
 2 
Study participants 3 
The study population included 64 index cases and additional affected and unaffected family 4 
members who were referred to our laboratory for SIL1 (MIM: 608005) mutation screening for 5 
suspected MSS. None of these individuals carried heterozygous or bi-allelic SIL1 variants 6 
with predicted or known pathogenicity. Thirty-five affected individuals presented with both 7 
early-onset cataracts and skeletal muscular disease and occasionally one or several additional 8 
symptoms or signs (most commonly ataxia, cerebellar atrophy, hypotonia, motor delay, 9 
intellectual disability, somatic growth retardation, spasticity, seizures, and microcephaly). 10 
Twenty-nine index cases exhibited only one of either early cataracts or skeletal muscular 11 
disease, always combined with one or more aforementioned additional symptoms and signs. 12 
The study was conducted in accordance with national legislations and was approved by 13 
institutional review boards in Munich, London, Newcastle and at the National Institutes of 14 
Health. Informed consent was obtained from the probands or their legal guardians. 15 
 16 
Reagents 17 
If not stated otherwise, reagents were obtained from Sigma-Aldrich. Sequences of 18 
oligonucleotide primers (Metabion) used in this study are available upon request. 19 
 20 
Whole-exome sequencing 21 
The index case of family A (II.3) underwent whole-exome sequencing on a Genome Analyzer 22 
HiSeq 2000 system (Illumina) after in-solution enrichment of exon and flanking intron 23 
sequences (SureSelect Human all Exon 50 Mb kit v4; Agilent) and indexing of samples for 24 
multiplex-sequencing (Multiplexing Sample Preparation Oligonucleotide Kit; Illumina). Read 25 
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alignment was performed with BWA v0.5.8 to the human genome assembly hg19. Single 1 
nucleotide variants and small insertions and deletions were called with SAMtools v0.1.7. 2 
Variant annotation was performed with custom Perl scripts, integrating data from dbSNP135 3 
and the UCSC Genome Browser Known Genes track. We excluded all nongenic, intronic 4 
(other than canonical splice sites) and synonymous variants, HapMap single nucleotide 5 
polymorphisms (SNP) present in dbSNP135 with an average heterozygosity greater than 0.02 6 
and variants present in >15 of >7,000 in-house exomes from individuals with unrelated 7 
diseases. Next, because a recessive disease model and a common ancestral allele (based on 8 
parental consanguinity) were expected, we gave priority to homozygous variants. 9 
 10 
Mutation detection in additional families 11 
The coding exons of INPP5K (RefSeq: NM_016532.3) were searched for mutations by 12 
sequencing of DNA samples of the index cases of twelve families homozygous for the chr17p 13 
locus or compatible with linkage to this region, and 21 isolated cases born to non-14 
consanguineous parents. Primers were designed using Primer3 software based on the Human 15 
Genome Browser genomic sequence of INPP5K. Sequences of PCR products were 16 
determined using the BigDye Terminator v3.1 Ready Reaction Cycle Sequencing Kit 17 
(Applied Biosystems) and capillary electrophoresis and detection on a 3730 DNA Analyzer 18 
(Applied Biosystems). 19 
 20 
Expression constructs 21 
Human INPP5K cDNA was amplified from human skeletal muscle mRNA and cloned in 22 
pAcGFP-C1 (for mammalian expression) and pGEX-4T-2 (for bacterial expression). INPP5K 23 
mutants were generated by site-directed mutagenesis 22 and verified by sequencing. The 24 
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expression vector for the ER marker mCherry-Sec61β (Addgene plasmid #49155) was a gift 1 
from Gia Voeltz 23. 2 
 3 
Cell culture and transfection 4 
COS-7 cells were cultured in Dulbecco’s Modified Eagle's medium (DMEM) containing 10% 5 
fetal calf serum, 2 mM glutamine, 40 U/mL penicillin and 0.04 mg/mL streptomycin. 6 
Transfection of COS-7 cells for live cell imaging was performed on 80% confluent cells 7 
plated on 35 mm glass bottomed dishes (MatTek) using Lipofectamine 2000 (Invitrogen) and 8 
constructs for GFP-INPP5K and mCherry-Sec61β. 9 
 10 
Fluorescence microscopy 11 
Live COS-7 cells cotransfected with GFP-tagged wild-type and mutant INPP5K and 12 
mCherry-Sec61β constructs were examined by fluorescence microscopy using a 3i-Marianas 13 
spinning disc confocal microscope (Intelligent Imaging Innovations). All constructs were 14 
transfected and imaged simultaneously in a single experiment. Ten to 15 random image fields 15 
were acquired at 40x magnification for each construct and 60-120 transfected cells per 16 
construct were assigned to one of three phenotypes by an investigator blind to the INPP5K 17 
genotype: reticular ER-like staining, punctate or partial ER-like staining and diffuse cytosolic 18 
staining. For whole-mount immunofluorescence staining, zebrafish embryos were fixed in 4% 19 
paraformaldehyde in phosphate-buffered saline (PBS) at 4°C overnight, blocked for 1 hr at 20 
room temperature (RT) in 5% horse serum in PBS, 0.1% Tween-20 before incubation 21 
overnight at 4°C with primary antibodies mouse anti-slow muscle myosin heavy chain (slow 22 
MyHc, clone F59, Developmental Studies Hybridoma Bank (DSHB); 1:50) and mouse anti-23 
fast muscle myosin heavy chain (fast MyHc, clone F310, DSHB; 1:200). Incubation with 24 
secondary antibody Alexa Fluor 488-conjugated goat anti-mouse immunoglobulin G (IgG) 25 
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(Thermo Fisher Scientific; 1:200) was performed for 1 hr at RT. Images were captured with a 1 
Nikon A1R confocal microscope (Nikon). 2 
 3 
Measurement of INPP5K phosphatase activity 4 
Wild-type and mutant GST-tagged full-length INPP5K was expressed in BL21 pLysS cells 5 
and purified on GSA beads (Thermo Fisher Scientific) in assay buffer (50 mM Tris-HCl, 6 
pH7.5, 150 mM NaCl, 10 mM MgCl2) plus 1% Triton X-100 and EDTA-free protease 7 
inhibitors (Roche Diagnostics). After washing, aliquots of beads were run on Coomassie gels 8 
to determine the abundance of full-length fusion proteins. Beads bearing equal amounts of 9 
fusion proteins were incubated in assay buffer containing 135 μM PtdIns(4,5)P2diC8 and free 10 
phosphate was measured using the Malachite Green assay kit (Echelon Biosciences). Results 11 
of three independent experiments were presented as mean + standard deviation. To minimize 12 
variability between purifications, all constructs were freshly prepared and purified in parallel 13 
for each experiment, and beads used in the assay were afterwards run on Coomassie gels to 14 
confirm equal protein loading. 15 
 16 
Structural model of INPP5K 17 
We modeled INPP5K structure by threading INPP5K sequence on the closest available 18 
orthologous crystal structures, OCRL (catalytic domain, Protein Data Bank (PDB): 4CMN) 19 
and NDP52 (SKICH domain, PDB: 3VVW), using the Phyre2 server 24. 20 
 21 
Zebrafish husbandry and observation 22 
We used the golden strain (slc24a5b1/+) of zebrafish (Zebrafish International Resource 23 
Center, Eugene, OR). Larvae were raised and staged as described 25. Video recordings of 24 
embryos were captured using a CMLN-13S2M camera (ClearView Imaging) mounted to a 25 
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Leica stereomicroscope (Leica). Light microscopy images were taken with a Leica dissection 1 
stereomicroscope equipped with a DFC 420C Leica digital camera (Leica). Touch-evoked 2 
swimming response was elicited by touching the embryos with a pipette tip. Measurements of 3 
the eye diameter and the head diameter (dorsal-ventral axis) were taken and a ratio between 4 
the two was calculated. One-tailed Student’s t-test was used to assess statistical significance. 5 
 6 
Antisense morpholino oligonucleotide knockdown 7 
Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools. The MOs 8 
were designed based on the sequence of the zebrafish INPP5K orthologs inpp5ka (RefSeq: 9 
XM_005157623.3) and inpp5kb (RefSeq: XM_005155275.3). We established splice-blocking 10 
MOs directed against the splice donor site of intron 4 of inpp5ka (5′-11 
CAGACTGAAGAGGAGCAGCATTCAA-3′) and against the splice donor site of intron 4 of 12 
inpp5kb (5′-TAGACTGGGACACATTTGCTCAGGT-3′). The Gene Tools standard control 13 
MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) was used as a negative control for the 14 
effects of MO injections. Embryos were injected with control MO (5 ng) or both anti-INPP5K 15 
MOs (2.5 ng of inpp5ka MO, 5 ng of inpp5kb MO) and efficient gene knockdown was 16 
verified by RT-PCR. Twenty-nine percent of non-injected embryos, 37% of embryos injected 17 
with control MO and 64% of inpp5ka+inpp5kb double-knockdown morphants were dead. 18 
Five independent MO injection experiments were performed for each MO and at least 500 19 
injected embryos were evaluated for each MO. 20 
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Results 1 
 2 
Bi-allelic mutations in INPP5K are associated with CMD with early-onset cataracts 3 
A consanguineous Bangladeshi multiplex family with two affected and four unaffected 4 
children (family A; Figure 1A) presented the possibility of locating the disease locus by 5 
linkage analysis. Genome-wide genotyping with approximately 300,000 SNP markers 6 
revealed two hits on chr10q11.22-10q21.1 and chr17p13.3-17p13.2 with a maximum LOD 7 
score of 2.27 (Figure S1). The 5.58-Mb region of interest on the short arm of chr17 was 8 
further supported by the results of short tandem repeat marker genotyping in twelve out of 43 9 
additional families suitable for haplotype analysis. A subgroup of these families was also 10 
tested for the potential chr10 locus; one out of 22 families was compatible with localization of 11 
so far unknown CMD mutations on chr10 (data not shown). 12 
We next performed whole-exome sequencing on the index case of family A. The 13 
average read depth was 129 with 94% of the targeted regions covered at least 20-fold. 14 
Following read alignment, variant calling, annotation and filtering we focused our analysis on 15 
non-synonymous homozygous variants located in the regions of interest on chr10q and chr17p 16 
and reduced potential disease-causing variants to two changes on chr17p. A c.149T>C 17 
[p.Ile50Thr] variant in INPP5K (RefSeq: NM_016532.3) (Figure 1A, Figure S2) was a non-18 
conservative change, affected a strictly conserved amino acid, was predicted to interfere with 19 
normal protein function by bioinformatic algorithms (Table S1) and was absent from 20 
databases (dbSNP146, Exome Aggregation Consortium (ExAC) and >7,000 in-house 21 
exomes). The second variant, c.1156C>G [p.Leu386Val] in SLC52A1 (RefSeq: 22 
NM_017986.3), was considered unlikely as it resulted in a conservative change of a non-23 
conserved amino acid, was predicted benign by bioinformatic algorithms and had a MAF of 24 
up to 0.5% in ExAC subpopulations. 25 
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We obtained further evidence for a causative role of INPP5K mutations when 1 
extending mutation screening to the twelve families homozygous for the chr17p locus or 2 
compatible with linkage to this region. Sanger sequencing of the INPP5K coding region 3 
yielded bi-allelic mutations in six pedigrees (families B-G, Figure 1A, Figure S2). Sanger 4 
sequencing of 21 isolated cases with non-consanguineous parents resulted in the identification 5 
of one individual carrying bi-allelic INPP5K mutations (family H, Figure 1A, Figure S2). 6 
Altogether, we found four different INPP5K mutations consisting of three missense mutations 7 
(c.149T>C [p.Ile50Thr], c.899A>G [p.Tyr300Cys] and c.1088T>C [p.Ile363Thr]) and one in-8 
frame deletion (c.881_883delCCT [p.Ser294del]) (Figure 1B). Whenever DNA from family 9 
members was available, we observed that the disease segregated with recessive inheritance of 10 
the INPP5K mutations (Figure 1A). 11 
In keeping with INPP5K mutations causing a condition affecting skeletal muscle and 12 
eye, we confirmed presence of mouse INPP5K in these tissues (Figure S3A). INPP5K is a 12-13 
exon gene encoding a 448-amino acid protein containing a 5-phosphatase domain 26. An 14 
additional C-terminal SKICH motif has been linked to targeting of INPP5K to the ER 15 
membrane 27; indeed we observed colocalization of INPP5K with ER membranes in COS-7 16 
cells cotransfected with GFP-INPP5K and the ER membrane marker mCherry-Sec61β (Figure 17 
S3B). The three missense mutations identified in our study affected strictly conserved amino 18 
acids and were predicted as deleterious to protein function or disease causing by 5/5 19 
bioinformatic algorithms (Table S1). The c.149T>C [p.Ile50Thr] and c.1088T>C 20 
[p.Ile363Thr] variants were not observed in public databases (dbSNP146, ExAC) and in in-21 
house exome datasets, which altogether allow interrogation of exome data of about 70,000 22 
individuals. For the c.899A>G [p.Tyr300Cys] and c.881_883delCCT [p.Ser294del] variants, 23 
there were single heterozygous samples among the 60,000 individuals in ExAC (MAF 24 
0.0000082; highest observed MAF in a subpopulation 0.00012 (East Asians) for p.Tyr300Cys 25 
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and 0.00015 (Finnish Europeans) for p.Ser294del). Both these samples probably represent 1 
carriers unaffected by INPP5K mutation-associated disease. 2 
 3 
INPP5K mutations result in a consistent and recognizable phenotype 4 
All individuals with identified bi-allelic INPP5K mutations presented with a homogeneous 5 
clinical picture including both CMD and early-onset cataracts, usually with mild intellectual 6 
disability but structurally normal cerebellum (Table 1, Figure 2A, B, C). Notably, linkage to 7 
chr17 or INPP5K mutations were excluded in 29 families and isolated cases presenting with 8 
an incomplete phenotype, i.e., either skeletal muscular disease or early cataracts together with 9 
variable additional clinical manifestations (mainly polyneuropathy, cerebellar atrophy or other 10 
brain malformations). Detection of INPP5K mutations in only eight out of 35 families and 11 
index cases with combined skeletal muscular disease and early-onset cataracts might be 12 
explained by INPPK variants that are missed by commonly applied diagnostic strategies (e.g., 13 
genomic re-arrangements or small deep intronic or regulatory variants), alternative effects of 14 
synonymous variants or locus heterogeneity. 15 
The presenting symptoms were early bilateral lens opacities, muscle weakness from 16 
birth, motor or global developmental delay or abnormal gait noted soon after independent 17 
walking had been acquired. Although affected individuals usually reached their motor 18 
milestones late, they all eventually acquired independent walking and muscle weakness, 19 
which was generally most prominent in proximal lower limb muscles, stabilized for several 20 
years. During course of the disease, motor capabilities appeared to deteriorate, and except for 21 
family A, elder cases (families D, F, H) had lost ambulation (Table 1). Five subjects 22 
developed respiratory compromise. No facial or oculomotor weakness or cardiac involvement 23 
was observed. Creatine kinase values were invariably markedly elevated (mean x7 of the 24 
upper normal limit, range x3 to x14). Electromyography (EMG) results in three affected 25 
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individuals were in accordance with a myopathic process while motor nerve conduction 1 
studies did not demonstrate substantial abnormalities. Muscle magnetic resonance imaging 2 
(MRI) in individual II.1, family H revealed progressive degenerative myopathy (Figure 2D, 3 
E). Cognitive deficits, usually mild, were recorded in eight case subjects while four 4 
individuals had normal intelligence. A few affected individuals had additional symptoms 5 
including contractures, scoliosis, spinal rigidity, microcephaly, hyperlaxity in finger joints, 6 
intention tremor, seizures or hygogonadism. No white matter and structural abnormalities of 7 
the brain were recorded except for II.1, family H who had widened inner and outer 8 
cerebrospinal liquor spaces but no focal alteration (Figure 2C), along with mild cognitive 9 
impairment. 10 
Muscle biopsies had been previously taken from nine individuals with INPP5K 11 
mutations for diagnostic purposes (Table 1). Muscle pathology was largely nonspecific, 12 
showing variable degrees of dystrophic features, including increased range of muscle fiber 13 
size with small and hypertrophic fibers, muscle fibrosis, excess adipose tissue, occasional 14 
fibers with internal nuclei, rare necrotic fibers and few basophilic (regenerating) fibers (Figure 15 
2F, Figure S4A, B). There were no abnormalities of blood vessels, inflammatory changes or 16 
group atrophy. Three biopsies showed variable numbers of vacuolated muscle fibers (Figure 17 
S4C, D, E). Some vacuoles presented with increased acid phosphatase and non-specific 18 
esterase activity or as rimmed vacuoles (Figure S4E). The distribution of fiber types was 19 
sometimes uneven with several fascicles displaying a type 1 or type 2 predominance. 20 
Oxidative enzyme localization was generally normal with no or only rare areas devoid of 21 
activity. No inclusions or excess storage material were seen. Immunohistochemistry for 22 
dystrophin, sarcoglycans, α-dystroglycan and laminin-α2 (merosin) was normal (Figure S4F, 23 
G). In some biopsies, cytoplasmic labeling for α-B crystallin, VCP and p62 as well as 24 
developmental and fetal myosin was observed in a variable proportion of fibers. Electron 25 
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microscopy was performed on two biopsies (II.3, family B and II.1, family H) and revealed 1 
several fibers with pronounced reduction of myofibrils and disrupted Z line material. Electron 2 
microscopy further confirmed the presence of occasional small vacuoles (Figure S4H), 3 
sometimes filled with myelin-like whorls as seen in rimmed vacuoles. In one of the two 4 
biopsies studied by electron microscopy (II.3, family B), several myonuclei had dense 5 
peripheral heterochromatin or were filled with osmiophilic material. Some of these abnormal 6 
nuclei also appeared to have an incomplete nuclear membrane or were surrounded by a dense 7 
membrane-like structure (Figure S4I). 8 
 9 
INPP5K mutants alter subcellular localization or impair phosphatase activity for PtdIns(4,5)P2 10 
Immunoblotting of protein preparations from C2C12 and COS-7 cells transfected with 11 
expression vectors for INPP5K wild-type and mutants showed no major effect of mutations 12 
on protein levels (Figure S5A, B). The mutants p.Ile50Thr, p.Ser294del and p.Tyr300Cys 13 
showed complete or partial perinuclear localization when overexpressed as GFP-fusion 14 
proteins in COS-7 cells (Figure 3A), largely indistinguishable from the wild-type protein, 15 
which is regularly located at the ER (Figure 3A, Figure S3B and 27). The p.Ile363Thr mutant 16 
affecting the SKICH motif, however, displayed a striking tendency for a more diffuse 17 
distribution in transfected cells (Figure 3A). 18 
INPP5K has been reported to dephosphorylate both PtdIns(4,5)P2 and PtdIns(3,4,5)P3, 19 
at the D-5 position, with marked preference for PtdIns(4,5)P2 28. We therefore performed in 20 
vitro measurement of catalytic activity using full-length recombinant wild-type INPP5K and 21 
mutants affecting the phosphatase domain (p.Ile50Thr, p.Ser294del, p.Tyr300Cys) together 22 
with PtdIns(4,5)P2diC8 as a substrate. We found that the disease-related phosphatase domain 23 
mutants and an artificial catalytically dead mutant p.Asp310Gly displayed reduced enzymatic 24 
activity (Figure 3B). While p.Tyr300Cys showed strongest impairment with activity almost as 25 
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low as the catalytically dead control, the two other mutants had retained a variable degree of 1 
residual catalytic activity. Modeling of INPP5K mutants on the crystal structure of the OCRL 2 
catalytic domain showed that the mutations did not directly alter the predicted INPP5K 3 
catalytic site (Figure 3C). Instead, they affected residues which were in the folding core of the 4 
predicted crystal structure and may therefore destabilize the overall shape of the phosphatase 5 
domain, indirectly rendering the enzyme inactive. 6 
Through metabolizing PtdIns(3,4,5)P3 INPP5K is thought to interfere with recruitment 7 
and activation of effector proteins such as the serine/threonine kinases Akt which regulate 8 
many signaling pathways 29. INPP5K overexpression has been reported to attenuate Akt 9 
phosphorylation in response to IGF-II and insulin stimulation 30-31. However, we noted no 10 
differences in Akt phosphorylation in IGF-II-treated human skin fibroblasts from individuals 11 
with the p.Ile50Thr mutation and control subjects (Figure S6). This discrepancy is probably 12 
related to the reported low activity of INPP5K towards PtdIns(3,4,5)P3 28. In line with this 13 
interpretation, we observed no INPP5K activity in the malachite green phosphatase assay with 14 
135 μM PtdIns(3,4,5)P3diC8 as substrate (data not shown). It seems possible that the low 15 
activity of INPP5K towards PtdIns(3,4,5)P3 may hamper reproducible detection of 16 
downstream effects in different experiments. 17 
 18 
Zebrafish inpp5ka+inpp5kb knockdown morphants replicate aspects of the human phenotype 19 
We identified two orthologs of INPP5K in zebrafish, inpp5ka and inpp5kb. Treatment with 20 
specific morpholinos reduced inpp5ka and inpp5kb expression at 48 hr post fertilization (hpf) 21 
(Figure S7). Macroscopically, inpp5ka+inpp5kb MO-injected embryos displayed altered tail 22 
morphology (curled and shortened tails, Figure 4A) and severely impaired swimming and 23 
touch-evoked escape response (data not shown), whereas control MO-injected embryos and 24 
non-injected embryos were largely indistinguishable. Inpp5ka+inpp5kb morphants also 25 
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showed a reduction in the size of their eyes compared to non-injected and control MO-1 
injected embryos (Figure 4B). Histologically, we observed abnormalities of skeletal muscle 2 
morphology in inpp5ka+inpp5kb-depleted embryos. Immunostaining of morphants for slow-3 
twitch and fast-twitch fibers showed disruption of the regular chevron shape of somites, 4 
curvature and distortion of both fiber types and abnormal myosepta (Figure 4C). In contrast, 5 
development of neuromuscular junctions progressed normally up to 48 hpf in 6 
inpp5ka+inpp5kb-deficient zebrafish embryos (Figure S8). 7 
 8 
INPP5K mutants do not alter ER-stress response and BiP interaction 9 
We noted that there were certain similarities between INPP5K-associated disease and MSS, 10 
both in terms of clinical features (early-onset cataracts, skeletal muscle involvement, variable 11 
intellectual disability 2) and muscle pathology (vacuolation and dense membranous structures 12 
associated with nuclei 4). Moreover, INPP5K is located at the ER 27 and MSS is related to ER 13 
dysfunction 32-33, leading to induction of the unfolded protein response (UPR), an ER stress 14 
reaction 34. We therefore used quantitative proteomics to measure abundances of well-15 
validated mammalian UPR markers. However, we did not observe major differences between 16 
skin fibroblasts from individuals with bi-allelic INPP5K mutations and control individuals 17 
(Figure S9). Very recently, INPP5K has been reported to interact with BiP 35, a master 18 
regulator of ER functions including the ER stress response 36. BiP is also involved in MSS 19 
pathophysiology as its activity is controlled by the cochaperone SIL1 37, the protein mutant in 20 
MSS 3; 38. By coprecipitation, we confirmed binding of wild-type INPP5K to BiP, but disease-21 
related INPP5K mutants bound equally well (Figure S10). 22 
 23 
INPP5K does not have a major impact on autophagy 24 
 
18
Some muscle biopsy findings in individuals with INPP5K mutations (vacuoles (sometimes 1 
rimmed) and accumulation of α-B crystallin and p62), the role of autophagy in the 2 
pathogenesis of skeletal muscular disease 39-43, and the function of PtdIns(4,5)P2 44 and 3 
INPP5K 45 in the regulation of autophagy prompted us to study this intracellular degradation 4 
system in a muscle biopsy (Figure S11A) and skin fibroblasts (Figure S11B, C) from 5 
individuals with INPP5K mutations. However, LC3B immunoblotting and 6 
immunofluorescence staining and measurement of LC3B turnover and p62 levels in 7 
fibroblasts treated with the autophagy inducer rapamycin and the lysosomal inhibitor 8 
bafilomycin A1 did not reveal specific effects of different INPP5K genotypes. 9 
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Discussion 1 
 2 
We identified bi-allelic missense and in-frame deletion mutations in INPP5K in eight families 3 
with a syndrome consisting of CMD, early-onset cataracts and mild intellectual disability. The 4 
pathogenic relevance of identified INPP5K variants is strongly supported by segregation with 5 
disease in several families, restriction to cases or extremely low prevalence in controls, 6 
impaired phosphatase activity for PtdIns(4,5)P2 and aberrant subcellular localization of 7 
mutant protein. The absence of INPP5K truncation mutations with clear loss of function may 8 
imply that variants in our series represent hypomorphic alleles; this is further supported by the 9 
observation of embryonic lethality in homozygous constitutive Inpp5k knockout mice 46. 10 
Replication of the human phenotype in zebrafish inpp5ka+inpp5kb double morphants, which 11 
manifested skeletal muscle and ocular abnormalities, lends further credence to this concept as 12 
targeting gene expression by morpholinos usually does not result in complete deficiency of 13 
the respective proteins. 14 
 15 
The clinical presentation of individuals with bi-allelic INPP5K mutations was relatively 16 
homogenous. The most salient features were bilateral cataracts that required surgery in the 17 
first years of life, predominantly proximal muscle weakness from birth and delayed motor or 18 
global development, first followed by rather stationary course of the disease but later 19 
progression to loss of ambulation, mild intellectual disability and elevated serum CK levels. 20 
Muscle biopsies of nine affected individuals revealed largely nonspecific dystrophic features 21 
consisting of variation in fiber size, fatty replacement and fibrosis. Clinical and muscle biopsy 22 
findings of similar cases have been reported earlier 47-48, and in one of these families we 23 
identified INPP5K mutations (family F). High serum CK levels and muscle histology were 24 
consistent with CMD rather than a form of clinically similar congenital myopathy, which 25 
typically features normal or near-normal serum CK concentrations and histological evidence 26 
 
20
of developmental or structural muscle changes 49. Muscle pathology in inpp5ka+inpp5kb 1 
zebrafish morphants was also indicative of skeletal muscle degeneration, again supporting a 2 
muscular dystrophy in individuals with INPP5K mutations and reinforcing the view that 3 
zebrafish can be used to model neuromuscular conditions 50. 4 
 5 
Although individuals with INPP5K mutations did not have cerebellar atrophy and ataxia, 6 
there was a clear phenotypic overlap with MSS (early cataracts, myopathy, cerebellar atrophy, 7 
variable intellectual disability). Histological examination of three diagnostic muscle biopsies 8 
from individuals with INPP5K mutations showed vacuoles in several myofibers, and electron 9 
microscopy of one biopsy revealed dense membranous structures associated with some 10 
myonuclei. Similar abnormalities have been reported in MSS caused by SIL1 mutations 2-4 11 
and Sil1-deficient mice 32. Since MSS is a disease of protein processing in the ER and since 12 
INPP5K is associated with ER membranes and interacts with BiP 35, a master regulator of ER 13 
functions 36, we considered a pathophysiological commonality of INPP5K-related disease 14 
with MSS. However, we found no evidence for induction of the ER stress response in skin 15 
fibroblasts from individuals with bi-allelic INPP5K mutations and disease-related INPP5K 16 
mutants did not interfere with interaction with BiP, suggesting still other mechanisms 17 
resulting in INPP5K-related disease. 18 
 19 
Currently established disease mechanisms in CMD are include disturbed formation of the 20 
extracellular matrix, impaired protein glycosylation, defective phosphatidylcholine 21 
biosynthesis as well as abnormalities of proteins of the ER and nuclear envelope 5. 22 
Abnormalities of phosphoinositide metabolism have not yet been described in CMD but in 23 
several other neuromuscular conditions including non-dystrophic myotubular myopathy 24 
caused by mutations in MTM1, encoding the phosphoinositide 3-phosphatase myotubularin 17. 25 
Phosphoinositide 5-phosphatases have not yet been implicated in skeletal muscle disorders, 26 
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but in a number of other conditions. One example is Lowe syndrome, an X-linked disorder 1 
caused by OCRL mutations 15. Boys with Lowe syndrome present with intellectual disability, 2 
epileptic seizures, kidney problems and congenital cataracts. While cataracts and intellectual 3 
disability are seen in both Lowe syndrome and individuals with INPP5K mutations, there are 4 
no abnormalities of the skeletal muscle in Lowe syndrome and individuals with INPP5K 5 
mutations did not have kidney disease despite the strong expression of INPP5K in this organ 6 
26. 7 
 8 
Our data from phosphatase assays were in accordance with earlier reports that INPP5K 9 
catalyzes the removal of the 5-phosphate from PtdIns(4,5)P2 28. By contrast, all three disease-10 
related INPP5K mutants affecting the catalytic domain showed significantly decreased 11 
phosphoinositide phosphatase activity. Modeling of mutants on the known crystal structure of 12 
the OCRL catalytic domain suggested that they do not directly alter the catalytic site of the 13 
enzyme. Instead, they are likely to change global folding of the phosphatase domain rendering 14 
it disordered and non-functional. The p.Ile363Thr mutant, which did not affect the 15 
phosphatase domain, showed abnormal localization away from the ER where wild-type 16 
INPP5K and the remaining mutants were located. This result is in line with this particular 17 
mutation occurring in the C-terminal SKICH domain, which is known to control INPP5K 18 
subcellular localization 27 most likely through binding to partner proteins. 19 
 20 
Impaired enzymatic function of INPP5K mutants suggested excess PtdIns(4,5)P2 in affected 21 
individuals’ cells. PtdIns(4,5)P2 has been linked to a wide array of molecular and cellular 22 
functions. As the substrate for receptor-regulated phospholipase C-mediated hydrolysis, its 23 
cleavage generates the secondary messengers Ins(1,4,5)P3 and diacylglycerol, which mobilize 24 
intracellular calcium and activate protein kinase C 7. In growth factor-activated cells, 25 
phosphoinositide 3-kinase converts PtdIns(4,5)P2 into PtdIns(3,4,5)P3, which is involved in 26 
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the regulation of cell death, cell cycle, actin polymerization, membrane ruffling, cell 1 
migration, and secretion 10; 51-53. As an intact phospholipid, PtdIns(4,5)P2 itself regulates 2 
membrane trafficking by recruiting protein complexes to the plasma membrane and multiple 3 
intracellular compartments 54-55. PtdIns(4,5)P2 functions extend to actin polymerization and 4 
focal adhesion assembly 56, channel and transporter regulation 57-58, virus budding 59, 5 
exocytosis 60, phagocytosis 61, endocytosis 9; 60, endosomal recycling 62 as well as 6 
endolysosomal trafficking and autophagosomal pathways 44; 63. 7 
 8 
The role of PtdIns(4,5)P2 in the control of autophagy was of interest as INPP5K has been 9 
linked to the regulation of autophagy in drosophila 45 and several aspects in muscle biopsies 10 
of individuals with INPP5K mutations were consistent with autophagic degeneration. 11 
However, we could not corroborate these observations by studying LC3B turnover and p62 12 
levels in a muscle biopsy and skin fibroblasts from individuals with INPP5K mutations. 13 
While further mechanisms related to PtdIns(4,5)P2 will soon be tested for their relevance in 14 
INPP5K pathophysiology, it is also possible that impaired dephosphorylation of PtdIns(4,5)P2 15 
is not the (most) relevant aspect leading to disease, and alternative INPP5K substrates or 16 
unknown INPP5K functions might be more important. Although we did not find differential 17 
regulation of Akt phosphorylation in IGF-II-stimulated cells from individuals with INPP5K 18 
mutations and controls, INPP5K appears to be involved in PtdIns(3,4,5)P3-dependent 19 
regulation of insulin signaling and glucose homeostasis in skeletal muscle 64. A recent study 20 
suggested that INPP5K regulates myoblast differentiation through the IGF-II-PI 3-kinase-21 
Akt-mTOR pathway 30. There are discrepancies concerning the effect of impaired INPP5K 22 
activity, leading to improved myoblast differentiation 30, contrasting with muscular dystrophy 23 
in individuals with INPP5K mutations. However, although unexpected in an autosomal 24 
recessive condition, the mutant INPP5K species may have acquired characteristics of a gain 25 
of abnormal function. Despite these limitations of our study, leaving the precise pathogenic 26 
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mechanisms to be determined, we have established compelling genetic evidence that INPP5K 1 
is essential for skeletal muscle structure and function. 2 
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Figure Legends 1 
 2 
Figure 1. INPP5K mutations in families with CMD and cataracts. (A) Pedigrees of families 3 
with identified homozygous or compound heterozygous INPP5K mutations. Squares represent 4 
males and circles represent females. Filled symbols represent affected individuals. INPP5K 5 
genotypes of individuals from whom a DNA sample was available are given below the 6 
pedigree symbols. Unaffected individuals were either heterozygous carriers or homozygous 7 
for the wild-type allele. +/+ = homozygous for mutation; +/- = heterozygous; -/- = 8 
homozygous for wild type. (B) Schematic representation of INPP5K and distribution of 9 
mutations. Amino acid numbering is shown below. 5-phosphatase = Inositol 5-phosphatase 10 
domain; SKICH = Skeletal muscle and kidney-enriched inositol phosphatase carboxyl 11 
homology domain. 12 
 13 
Figure 2. Clinical, imaging and muscle biopsy findings of individuals with bi-allelic INPP5K 14 
mutations. (A) Individual II.1, family G, at age 7 years. Note mild atrophy of the shoulder 15 
girdle muscles and posterior compartment of the thighs. (B) Individual II.1, family H, at age 16 
41 years. Standing independently was only possible with wide stance and the arms could not 17 
be lifted above the head (maximum arm elevation 45°) due to proximal upper and lower limb 18 
weakness. Hunchback and marked atrophy of scapuloperoneal and dorsal proximal leg 19 
muscles were noted. (C) Individual II.1, family H, at age 25 years. Sagittal T1-weighted, 20 
contrast-enhanced cranial MRI revealed mild global brain atrophy not appropriate for age but 21 
normal cerebellar architecture. (D) Individual II.1, family H, at age 41 years. Whole-body T1-22 
weighted MRI showed marked muscle atrophy and fatty degeneration, predominantly in 23 
proximal arm and leg muscles. (E) Individual II.1, family H., at age 25 years (upper panel) 24 
and age 41 years (lower panel). Cross-sectional T1-weighted MRI of the thighs revealed 25 
progressive muscle atrophy and fatty degeneration, most severe in M. vastus medialis, M. 26 
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rectus femoris, M. semimembranosus and adductor muscles. (F) Muscle biopsy from 1 
individual II.2, family G, taken at age 3 years (site of biopsy not documented). H&E stain 2 
showed marked variation in fiber size, rounding of fibers, increased endomysial collagen and 3 
some fatty degeneration. Scale bar = 50 μm. 4 
 5 
Figure 3. Structural and functional consequences of INPP5K mutants. (A) Subcellular 6 
localization of INPP5K mutants. Live COS-7 cells cotransfected with the ER marker 7 
mCherry-Sec61β (red) and GFP-tagged wild-type or mutant INPP5K constructs were imaged 8 
and assigned to one of three categories by an observer blinded to the genotype. Phosphatase 9 
domain mutants did not have a strong effect on protein targeting to the ER, appearing 10 
substantially like the wild-type fusion protein. Conversely, the p.Ile363Thr mutation in the 11 
SKICH domain caused the GFP signal to become punctate or diffuse cytosolic in almost all 12 
cells. At least 60 randomly selected cells were assessed per INPP5K construct in one 13 
experiment by an observer unaware of the INPP5K genotype. Scale bars = 50 μm. (B) GST-14 
INPP5K phosphatase activity on 135 μM PtdIns(4,5)P2diC8. Disease mutants affecting the 15 
phosphatase domain interfere with enzyme activity. The variant p.Asp310Gly is an artificial 16 
mutant predicted to result in a catalytically dead protein through altering the active centre. 17 
Bars represent mean values of three independent experiments and error bars represent 18 
standard deviations. (C) Model of predicted INPP5K crystal structure (Phyre2). Mutated 19 
residues (yellow) were located outside the active centre of the enzyme (red) but appeared to 20 
affect residues in the folding core of the 5-phosphatase domain and in the SKICH motif. 21 
 22 
Figure 4. Defects in zebrafish inpp5ka+inpp5kb double morphants at 48 hpf. (A) Live 23 
embryos injected with control MO, inpp5ka MO and inpp5kb MO or left untreated (non-24 
injected). More than 95% of non-injected embryos and embryos injected with control MO 25 
showed no macroscopic abnormalities. Images for inpp5ka+inpp5kb morphants represent 26 
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mild (left, 15% of living embryos), moderate (middle, 24% of living embryos) and severe 1 
(right, 44% of living embryos) defects in terms of length and curvature of tails. At least 150 2 
living embryos were counted per condition. Scale bars = 500 µm. (B) Eye-to-head ratio of 3 
zebrafish embryos at 48 hpf. Eye diameter (white line) and head diameter (red line) were 4 
measured in the dorsal-ventral axis and ratios were calculated. Scale bars: = 250 μm. Graphs 5 
represent mean values of ratios obtained with 10 embryos and error bars represent standard 6 
deviations. The statistical difference between non-injected and control MO-injected embryos 7 
and inpp5ka+inpp5kb double morphants is indicated: n.s. = not significant, *** = P <0.001 8 
(one-tailed Student’s t-test). (C) Whole-mount immunostainings of zebrafish embryos at 48 9 
hpf using antibodies against slow muscle myosin heavy chain (slow MyHc) and fast muscle 10 
myosin heavy chain (fast MyHc). Images for inpp5ka+inpp5kb morphants represent mild, 11 
moderate and severe phenotypes (from left to right) as staged macroscopically. 12 
Inpp5ka+inpp5kb-deficient embryos displayed muscle fiber defects and loss of the chevron 13 
shape of somites. The normal straight alignment of slow twitch muscle fibers was disrupted in 14 
inpp5ka+inpp5kb double knockdown morphants. Fibers appeared wavy and deformation of 15 
myosepta was observed in severe phenotypes (arrows). Staining for fast twitch muscle fibers 16 
also showed distortion and defects of fibers and severe alterations of myosepta (arrows). Scale 17 
bars = 50 μm. 18 
 19 
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Table 1 Clinical features of individuals with bi-allelic INPP5K mutations. 
 
Family Subject Sex Age Ethnic 
origin 
Consan-
guinity 
INPP5K 
mutation 
Initial 
presenting 
symptom 
(at age) 
Cataracts 
(age at 
diagnosis)
Hypo-
tonia 
Delayed 
motor 
milestones
Muscle 
weakness/ 
atrophy 
Best 
motor 
ability 
CK (x 
upper 
normal 
limit) 
EMG Muscle 
biopsy 
Intellectual 
disability 
Brain 
abnormality
Respiratory/ 
cardiac 
involvement 
Other findings 
IV.3 F 21 y motor de-
velopmental 
delay (15 m)
+ (6 y) + + +/n. a., 
P>D, 
LL>UL 
2 x4.5 n. d. dystrophic mild - -/- contractures 
(ankle), scoliosis 
A 
IV.4 F 22 y 
Bangladesh + p.[Ile50Thr];[
Ile50Thr] 
motor de-
velopmental 
delay (15 m)
+ (4 y) + + +/n. a., 
P>D, 
LL>UL 
2 x8.5 n. d. n. d. moderate n. d. +/- contractures 
(ankle), scoliosis 
B II.3 M 8.5 y Bangladesh + p.[Ile50Thr];[
Ile50Thr] 
global de-
velopmental 
delay (10 m)
+ (12 m) + + +/-, P>D, 
LL>UL 
2 x5 n. d. myopathic moderate - +/- S. aureus sepsis 
and meningitis at 
age 4 m 
C II.1 M 11 y Bangladesh + p.[Ile50Thr];[
Ile50Thr] 
cataracts 
(4 y) 
+ (4 y) - - +/n. a., 
P>D, 
LL>UL 
2 x4.5 n. d. n. d. mild - +/- - 
III.1 F 35 y walking dif-
ficulty (2 y)
+ (3 y) + + +/-, P>D, 
LL>UL 
4 x4 n. d. myopathic - n. d. +/- spinal rigidity, 
contractures 
D 
III.6 M 25 y 
Pakistan - p.[Ile50Thr];[
Ile50Thr] 
cataracts 
(1.5 y) 
+ (1.5 y) + - +/n. a.. 
P>D, 
LL>UL 
4 n. d. n. d. n. d. - n. d. -/- spinal rigidity, 
hyperlaxity in 
finger joints 
E II.1 F 9.5 y Pakistan + p.[Ile50Thr];[
Ile50Thr] 
global de-
velopmental 
delay (2.5 y)
+ (5 y) + + +/+ 2 x10 n. d. myopathic mild - -/- intention tremor, 
microcephaly 
(mild) 
II.1 F 37 y hypotonia 
(birth) 
+ (6 m) + + +/+, P>D 4 x4 myopathic dystrophic mild - -/- microcephaly, 
kyphosis, con-
tractures (knee, 
ankle) 
F 
II.2 M 35 y 
Brazil - p.[Ser294del];
[Ile363Thr] 
hypotonia 
(birth) 
+ (6 m) + + +/+, P>D 4 x3 n. d. dystrophic mild - -/- microcephaly, 
kyphosis, con-
tractures (knee, 
ankle), seizures 
II.1 M 7 y hypotonia, 
motor delay 
(birth) 
+ (early 
childhood)
+ + +/+, P>D, 
LL>UL 
2 x14 myopathic myopathic - - -/- - G 
II.2 F 6 y 
Pakistan + p.[Ile50Thr];
[Ile50Thr] 
hypotonia, 
motor delay 
(birth) 
+ (early 
childhood)
+ + +/+, P>D, 
LL>UL 
2 n. d. n. d. myopathic - - -/- - 
H II.1 F 41 y Germany - p.[Tyr300Cys];
[Tyr300Cys] 
motor de-
velopmental 
delay (1 y) 
+ (5 y) + + +/+, P>D 4 x12 myopathic vacuolar 
myopathy 
mild mild global 
brain atrophy
+/- hypogonadism 
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Legend to Table 1: F = Female; M = Male; m = Month(s); y = Year(s); + = Present; - = Not present; n. a. = Not available; n. d. = Not determined; 
CK = Serum creatine kinase; P>D = Proximal muscles more severely affected than distal muscles; LL>UL = Lower limb muscles more severely 
affected than upper limb muscles; Best motor ability: 0 = Normal walking, running and jumping; 1 = Normal walking, no running and jumping; 2 = 
Walks longer distances unsupported, abnormal gait; 3 = Walks a few steps unsupported, requires walking aids or wheelchair for longer distances; 4 = 
Walks only with walking aids or uses wheelchair most of the time; 5 = Wheelchair bound. 
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Figure S1. Genome-wide linkage analysis of family A. 
 
 
 
 
 
 
Genome-wide SNP genotyping was performed using the Illumina 300K chip (Illumina). 
Multipoint linkage was calculated with ALLEGRO 1 assuming autosomal recessive 
inheritance, a frequency of the deleterious allele of 0.001, and complete penetrance. The 
region of interest on chr10 spanned 7.18 Mb and contained 42 RefSeq genes. The candidate 
region on chr17 spanned 5.58 Mb and contained 98 RefSeq genes. 
Figure S2. INPP5K mutations identified in individuals with CMD and cataracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequencing electropherograms for comparison of nucleotide sequences of individuals affected 
with CMD and cataracts and unaffected control individuals. 
Figure S3. Tissue distribution and localization of INPP5K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Tissues from young adult C57BL/6J mice (P56) were homogenized with a rotor-stator 
homogenizer (TissueRuptor, Qiagen) in 1x PBS containing 1% SDS as well as protease 
(Complete Protease Inhibitor; Roche Diagnostics) and phosphatase inhibitors (PhosSTOP; 
Roche Diagnostics). Protein preparations were incubated at 95°C for 5 min, debris was 
removed by 5 min centrifugation at 14,000 rpm at 4°C, and protein concentrations in the 
supernatants were measured with a BCA protein assay (Thermo Fisher Scientific). Protein 
samples were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
and transferred to a nitrocellulose membrane (Protran; GE Healthcare). Transferred proteins 
were blocked for 1 hr at RT in TBS-T with 5% non-fat milk and then incubated overnight at 
4°C with goat anti-INPP5K antibody (C19; Santa Cruz Biotechnology; 1:200). Subsequently, 
the blot was incubated with horseradish peroxidise (HRP)-conjugated donkey anti-goat IgG 
antibody (Jackson ImmunoResearch; 1:10,000) for 1 hr at RT. Bands were detected with an 
ECL Detection Kit (GE Healthcare). A lysate from COS-7 cells transfected with an 
expression vector coding for a GFP-INPP5K fusion protein was used as a control. EDL = 
extensor digitorum longus muscle; soleus = soleus muscle; eye = whole eye tissue; * = 
endogenous INPP5K; ** = GFP-INPP5K fusion protein; MW = Molecular weight in kilo 
Dalton. (B) In live-imaged transfected COS-7 cells, the ER marker mCherry-Sec61β (red) 
colocalizes extensively with wild-type GFP-INPP5K (green). Images show a higher 
magnification of a detail of Figure 3A (left panel). Scale bars = 10 μm. 
Figure S4. Muscle biopsy from individuals with bi-allelic INPP5K mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A, B) H&E stain revealing variation in fiber size, rounding of fibers, increased endomysial 
collagen and some degree of fatty degeneration. (C, D) H&E stain, (E) Gomori trichrome 
stain showing vacuolated muscle fibers. With Gomori trichrome, some vacuoles contained 
red-stained material. (F) α-dystroglycan (clone VIA4-1) and (G) Laminin-α2 (clone 2H5) 
immunostainings gave positive results. (H) Electron micrograph showing a vacuole associated 
with myelin-like whorls and osmiophilic material. (I) Electron micrograph of nuclei in a 
degenerating muscle fiber, one with dense peripheral heterochromatin (left) and one partially 
surrounded by an electron-dense membranous structure (right). (A): left M. vastus lateralis 
from individual IV.3, family A, taken at age 6 years, (B-E, F, G): left M. biceps brachii from 
individual II.1, family H, taken at age 25 years), (H, I): left quadriceps muscle from 
individual II.3, family B, taken at age 4 years). Scale bars (A, B, F, G) = 50 μm, (C-E) = 10 
μm, (H) = 0.5 μm, (I) = 2 μm. 
Figure S5. Levels of wild-type and mutant INPP5K in transfected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Human INPP5K cDNA was amplified from human skeletal muscle mRNA and cloned in 
pCMV-Myc. INPP5K mutants were generated by site-directed mutagenesis and verified by 
sequencing. C2C12 cells were cultured in DMEM containing 10% fetal calf serum, 2 mM 
glutamine, 40 U/mL penicillin and 0.04 mg/mL streptomycin. Cells were cotransfected with 
Myc-tagged INPP5K expression constructs and an empty GFP expression plasmid 
(transfection efficiency control) using Amaxa Cell Line Nucleofector Kit V (Lonza). Cultured 
cells were lysed in cell lysis buffer (1% SDS, 10 mM Tris-HCl, pH 7.4) containing protease 
and phosphatase inhibitors. Protein preparations were incubated at 95°C for 5 min, debris was 
removed by 5 min centrifugation at 14,000 rpm at 4°C, and protein concentrations in the 
supernatants were measured with a BCA protein assay. Equal amounts of total protein were 
separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membranes. Membranes were blocked for 1 hr at RT in TBS-T with 5% non-fat milk and then 
incubated overnight at 4°C with primary antibodies mouse anti-Myc (Clontech; 1:1,000), 
rabbit anti-GFP (Abcam; 1:1,000) and rabbit anti-GAPDH (Merck Millipore; 1:500). 
Subsequently, blots were incubated with HRP-conjugated goat anti-mouse IgG and goat anti-
rabbit IgG antibodies (both from Invitrogen; 1:5,000) for 1 hr at RT. Bands were detected 
with an ECL Detection Kit. Densitometry to quantify INPP5K levels was performed using 
ImageJ software. Signals obtained for INPP5K were normalized to GFP (transfection 
efficiency control) and GAPDH (loading control). Bars represent means of three independent 
experiments and error bars represent standard deviations. MW = Molecular weight in kilo 
Dalton. (B) Same analysis using COS-7 cells. Experimental conditions were identical to those 
described in (A) except for transfection of cells using JetPei Transfection Reagent (Peqlab) 
instead of nucleofection. 
Figure S6. Akt phosphorylation in IGF-II-stimulated primary human skin fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skin fibroblasts from three individuals homozygous for the INPP5K mutation p.Ile50Thr 
(II.1, family C, III.1, family D and III.6, family D) and three healthy subjects were obtained 
from the MRC Centre for Neuromuscular Diseases Biobank, Newcastle, UK. Cells were 
cultured in DMEM containing 10% fetal calf serum, 2 mM glutamine, 40 U/mL penicillin and 
0.04 mg/mL streptomycin. Prior to cell lysis, cultures were kept in serum-free DMEM for 48 
hr and then stimulated with 200 ng/mL IGF-II (Merck Millipore) for 1 hr 2. Cells were lysed 
in cell lysis buffer supplemented with protease and phosphatase inhibitors. Protein 
preparations were incubated at 95°C for 5 min, debris was removed by 5 min centrifugation at 
14,000 rpm at 4°C, and protein concentrations in the supernatants were measured with a BCA 
protein assay. Equal amounts of total protein were run on SDS-polyacrylamide gels and 
blotted onto nitrocellulose membranes. Membranes were blocked for 1 hr at RT in TBS-T 
with 5% non-fat milk and then incubated overnight at 4°C with primary antibodies mouse 
anti-Akt, rabbit anti-phospho-Akt (Ser473) (both from Cell Signaling Technology; 1:2,000) 
and rabbit anti-GAPDH. Subsequently, blots were incubated with HRP-conjugated goat anti-
mouse IgG and goat anti-rabbit IgG antibodies for 1 hr at RT. Bands were detected with an 
ECL Detection Kit. MW = Molecular weight in kilo Dalton. 
Figure S7. MO-mediated double knockdown of inpp5ka and inpp5kb in zebrafish. 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR analysis of inpp5ka and inpp5kb transcripts from 48-hpf embryos injected with 
splice-blocking inpp5ka and inpp5kb MOs. RNA was isolated with Trizol reagent 
(Invitrogen). Reverse transcription was performed with the Superscript III First-Strand 
Synthesis System (Invitrogen). Target sequences were PCR-amplified using specific 
oligonucleotide primers, run on agarose gels and detected by SafeView Nucleic Acid Stain 
(NBS Biologicals). Top panel: Downregulation of inpp5ka in both the single and double 
knockdown was demonstrated with inpp5ka-specific PCR primers. Middle panel: Mis-spliced 
inpp5kb transcripts alongside small amount of retained wild-type transcript were detected in 
the single and double knockdown with inpp5kb-specific PCR primers. Bottom panel: Ef1α 
was used as an internal RT-PCR control to exclude variations in cDNA synthesis quality. MW 
= Molecular weight in base pairs. 
Figure S8. Neuromuscular junction morphology in inpp5ka+inpp5kb morphants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For whole-mount immunofluorescence staining, 48-hpf zebrafish embryos were fixed in 4% 
paraformaldehyde in PBS at 4°C overnight and blocked for 1 hr at RT in 5% horse serum in 
PBS, 0.1% Tween-20. Presynaptic motor nerve endings were visualized by incubation with 
mouse anti-synaptic vesicle protein 2 antibody (SV2, DSHB; 1:200) overnight at 4°C 
followed by Alexa Fluor 488-conjugated goat anti-mouse IgG antibody for 1 hr at RT. 
Acetylcholine receptors (AChR) were labelled with Alexa Fluor 594-conjugated α-
bungarotoxin (Thermo Fisher Scientific; 1:1,000). Images were captured with a Nikon A1R 
confocal microscope (Nikon). Images for inpp5ka+inpp5kb morphants represent mild, 
moderate and severe phenotypes (from left to right) as staged macroscopically. Both in 
controls and in inpp5ka+inpp5kb morphants, motor axons had made branches into somites 
where they formed contacts with AChR clusters. Scale bars = 50 μm. 
Figure S9. Quantification of ER stress response markers. 
 
 
 
 
 
 
 
 
 
 
 
Skin fibroblasts from three individuals homozygous for the INPP5K mutation p.Ile50Thr 
(II.1, family C, III.1, family D and III.6, family D) and three healthy subjects were obtained 
from the MRC Centre for Neuromuscular Diseases Biobank, Newcastle, UK. Cells were 
cultured in DMEM containing 10% fetal calf serum, 2 mM glutamine, 40 U/mL penicillin and 
0.04 mg/mL streptomycin. Cells were lysed in 1% SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 
7.8 containing protease and phosphatase inhibitors, and protein extracts were treated with 
benzonase (Merck Millipore) for 30 min at 37°C. Protein preparations were incubated at 95°C 
for 5 min, debris was removed by 30 min centrifugation at 18,000g at 4°C, and protein 
concentrations in the supernatants were measured with a BCA protein assay. Protein extracts 
were treated with 10 mM dithiothreitol for 30 min at 56°C followed by incubation with 30 
mM iodoacetamide for 20 min at RT. Samples were digested with trypsin using filter-aided 
sample preparation 3-4 and then analyzed on an Ultimate 3000 nano RSLC system coupled to a 
Q Exactive HF mass spectrometer (Thermo Fisher Scientific) in parallel reaction monitoring 
mode. Peptides were pre-concentrated on a PepMap 100 µm x 2 cm C18 trapping column 
(Thermo Fisher Scientific) for 10 min using 0.1% trifluoroacetic acid at a flow rate of 20 
µL/min, followed by separation on a PepMap 75 µm x 50 cm C18 main column (Thermo 
Fisher Scientific) with a 55 min gradient ranging from 5-42% of 84% acetonitrile, 0.1% 
formic acid at a flow rate of 250 nL/min. Mass spectra were acquired in the Orbitrap at a 
resolution of 30,000 with an automatic gain control target of 3 x 106, a maximum injection 
time of 100 ms, an isolation width of 0.4 m/z and a normalized collision energy of 27 in 
scheduled mode. Raw data was evaluated with Skyline software 5 and peak selection and 
assignment were manually validated. Unique peptides of proteins whose levels are altered 
under conditions of ER stress 6-7, calreticulin, calnexin, endoplasmin, BiP (GRP78), HYOU1 
(GRP170), ERdj3, SEC61α1 and SEC62, were compared against an in-house spectral library. 
Peptide peak areas were used to determine median abundance of each protein of interest 
across all target protein-related peptides detected in two technical replicates of cases and 
controls. Median values were normalized to the median value calculated for proteome-wide 
peptides from the case or control group. Data are presented as the ratio cases median protein 
level/controls median protein level, plotted in logarithmic scale base 2. The counts of unique 
peptides for individual proteins are given in box brackets after the protein names. 
Figure S10. Coprecipitation of BiP with INPP5K from transfected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COS-7 cells were cotransfected with expression vectors for GFP-tagged INPP5K (or empty 
GFP vector) and Myc-tagged BiP (Addgene plasmid #27164, a gift from Ron Prywes 8) using 
JetPei Transfection Reagent. Cells were lysed in 150 mM NaCl, 0.5 mM EDTA, 10 mM Tris-
HCl, pH 7.5, 0.5% NP-40 supplemented with protease and phosphatase inhibitors. Protein 
extracts were incubated at 95°C for 5 min, debris was removed by 5 min centrifugation at 
14,000 rpm at 4°C, and protein concentrations in the supernatants were measured with a BCA 
protein assay. Five hundred μg of total protein were mixed with GFP binding protein coupled 
to magnetic agarose beads (GFP-Trap 9; ChromoTek) and left on a rotator for 1 hr at 4°C. 
Beads were magnetically separated, washed, resuspended in SDS sample buffer and boiled to 
elute bound proteins. Proteins were resolved by SDS-polyacrylamide gel electrophoresis, 
blotted onto PVDF membranes (Hybond; GE Healthcare) and transferred proteins were 
blocked for 1 hr at RT in TBS-T with 5% non-fat milk. To determine protein levels in 
transfected cells (Input) as well as amounts of precipitated GFP-INPP5K (or GFP alone) and 
bound Myc-BiP (GFP-Trap), membranes were incubated overnight at 4°C with primary 
antibodies mouse anti-Myc and rabbit anti-GFP followed by HRP-conjugated goat anti-mouse 
IgG and goat anti-rabbit IgG antibodies for 1 hr at RT. Bands were visualized with an ECL 
Detection Kit. 
Figure S11. Measurement of autophagy in skeletal muscle and cultured skin fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Detection of LC3B in muscle biopsies from individual II.1, family H (homozygous 
INPP5K mutation p.Tyr300Cys), and healthy and pathological controls. Eight-μm cryostat 
sections  of  deep-frozen unfixed  tissue  samples  were  fixed  with  4%  paraformaldehyde, 
pH 7.4, for 10 min at RT, permeabilized with 0.1% Triton X-100 for 15 min and blocked in 
5% horse serum in PBS for 1 hr at RT. Specimens were incubated at 4°C overnight with 
rabbit anti-LC3B antibody (Novus Biologicals; 1:100), followed (continued on next page) 
(legend to Figure S11, continued from previous page) by Alexa Fluor 488-conjugated donkey 
anti-rabbit IgG antibody (Jackson ImmunoResearch; 1:500) for 1 hr at RT. Images were 
captured with a Zeiss Axiovert 200 M fluorescence microscope and a Zeiss AxioCam HR 
camera (Zeiss). For immunoblotting, skeletal muscle biopsy specimens were homogenized 
with a rotor-stator homogenizer in 1x PBS containing 1% SDS. Protein preparations were 
incubated at 95°C for 5 min, debris was removed by 5 min centrifugation at 14,000 rpm at 
4°C, and protein concentrations in the supernatants were measured with a BCA protein assay. 
Equal amounts of total protein were separated on SDS-polyacrylamide gels and blotted onto 
PVDF membranes. Membranes were blocked for 1 hr at RT in TBS-T with 5% non-fat milk 
and then incubated overnight at 4°C with rabbit anti-LC3B (Novus Biologicals; 1:1,000) and 
rabbit anti-GAPDH antibodies. Subsequently, blots were incubated with HRP-conjugated goat 
anti-rabbit IgG antibody for 1 hr at RT. Bands were detected with an ECL Detection Kit. .* = 
LC3B-I, ** = LC3B-II. MW = Molecular weight in kilo Dalton. (B) Detection of LC3B in 
primary skin fibroblasts. Skin fibroblasts from three individuals homozygous for the INPP5K 
mutation p.Ile50Thr (II.1, family C, III.1, family D and III.6, family D) and two healthy 
subjects were obtained from the MRC Centre for Neuromuscular Diseases Biobank, 
Newcastle, UK. Cells were cultured in DMEM containing 10% fetal calf serum, 2 mM 
glutamine, 40 U/mL penicillin and 0.04 mg/mL streptomycin. Cells were lysed in 
radioimmunoprecipitation assay buffer (1% Triton X-100, 0.5% sodium deoxycholate, 1% 
SDS, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) containing protease and phosphatase 
inhibitors. Protein preparations were incubated at 95°C for 5 min, debris was removed by 5 
min centrifugation at 14,000 rpm at 4°C, and protein concentrations in the supernatants were 
measured with a BCA protein assay. Equal amounts of total protein were run on SDS-
polyacrylamide gels and transferred to PVDF membranes. Membranes were blocked for 1 hr 
at RT in TBS-T with 5% non-fat milk and then incubated overnight at 4°C with primary 
antibodies rabbit anti-LC3B and rabbit anti-GAPDH. Subsequently, blots were incubated with 
HRP-conjugated goat anti-rabbit IgG antibody for 1 hr at RT. Bands were detected with an 
ECL Detection Kit. MW = Molecular weight in kilo Dalton. (C) LC3B conversion and p62 
levels in primary skin fibroblasts treated with autophagy modifiers. In addition to the 
procedures described in (B), cells were treated with 100 nM bafilomycin A1, 100 nM 
rapamycin or vehicle (DMSO) for 12 hr prior to cell lysis 10. For detection of p62, a rabbit 
anti-p62 antibody (Sigma-Aldrich; 1:1,000) was used. 
Table S1. Bioinformatic results for INPP5K amino acid substitutions. 
 
 
The score given by MutationTaster 11 is the probability of the prediction, i.e. a value close to 1 
indicates a high “security” of the prediction. For PolyPhen-2 12, scores near 1.0 are most 
strongly predicting a deleterious effect of an amino substitution. SIFT 13 scores < 0.05 are 
assigned the prediction “damaging”. SNAP2 14 scores range from -100 strong neutral 
prediction to +100 strong effect prediction. Values for the LRTnew 15 score range from 0 to 1 
with higher values indicating a variant is more likely to be deleterious. GERP++ 16 estimates 
evolutionary constraint of specific positions. Scores range from -12.3 to 6.17 with higher 
scores indicating more conserved sites. PhyloP 17 conservation scores are based on the 
multiple alignment of vertebrate genomes. Scores range from -5.172 to 1.062 and higher 
scores suggest stronger conservation of the site. 
Mutation Mutation 
Taster pre-
diction / score 
PolyPhen-2 
prediction / 
score 
SIFT 
prediction / 
score 
SNAP2 
prediction / 
score 
LRT 
prediction / 
LRTnew score 
GERP++ 
score 
PhyloP 
score 
p.Ile50Thr Disease 
causing / 1 
Probably 
damaging / 
0.999 
Damaging / 
0 
Effect / 7 Deleterious / 
1 
5.4 1.062 
p.Tyr300Cys Disease 
causing / 1 
Probably 
damaging / 1 
Damaging / 
0 
Effect / 89 Deleterious / 
1 
5.53 0.991 
p.Ile363Thr Disease 
causing / 1 
Probably 
damaging / 1 
Damaging / 
0 
Effect / 22 Deleterious / 
1 
5.94 1.003 
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